CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
2.62
2.24%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.14
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.021941 %
Charges from full value of position ($-4.17)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.021941%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.000281 %
Charges from full value of position ($-0.05)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.000281%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency SEK
Margin 5%
Stock exchange Sweden
Commission on trade 0%

*Information provided by Capital.com

Medivir AB ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 2.68
Open* 2.66
1-Year Change* -66.92%
Day's Range* 2.62 - 2.66
52 wk Range 2.45-8.07
Average Volume (10 days) 875.92K
Average Volume (3 months) 6.22M
Market Cap 337.28M
P/E Ratio -100.00K
Shares Outstanding 67.10M
Revenue 5.71M
EPS -1.11
Dividend (Yield %) N/A
Beta 0.21
Next Earnings Date Feb 15, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 27, 2024 2.68 -0.04 -1.47% 2.72 2.72 2.68
Mar 26, 2024 2.76 0.08 2.99% 2.68 2.78 2.68
Mar 22, 2024 2.72 0.00 0.00% 2.72 2.74 2.70
Mar 21, 2024 2.72 -0.02 -0.73% 2.74 2.74 2.70
Mar 20, 2024 2.78 0.02 0.72% 2.76 2.78 2.74
Mar 19, 2024 2.76 -0.06 -2.13% 2.82 2.82 2.76
Mar 18, 2024 2.82 0.00 0.00% 2.82 2.82 2.80
Mar 15, 2024 2.66 -0.04 -1.48% 2.70 2.72 2.66
Mar 14, 2024 2.70 0.02 0.75% 2.68 2.70 2.68
Mar 13, 2024 2.70 0.00 0.00% 2.70 2.70 2.70
Mar 12, 2024 2.66 -0.04 -1.48% 2.70 2.70 2.66
Mar 11, 2024 2.70 0.00 0.00% 2.70 2.70 2.66
Mar 8, 2024 2.66 -0.16 -5.67% 2.82 2.82 2.66
Mar 7, 2024 2.78 0.04 1.46% 2.74 2.84 2.74
Mar 6, 2024 2.82 -0.14 -4.73% 2.96 2.96 2.82
Mar 5, 2024 2.92 0.00 0.00% 2.92 2.94 2.88
Mar 4, 2024 2.92 0.00 0.00% 2.92 2.92 2.92
Mar 1, 2024 3.02 -0.06 -1.95% 3.08 3.08 3.00
Feb 29, 2024 3.04 -0.04 -1.30% 3.08 3.10 3.04
Feb 28, 2024 3.10 -0.04 -1.27% 3.14 3.14 3.08

Medivir B Events

Time (UTC) Country Event
Tuesday, April 30, 2024

Time (UTC)

10:59

Country

SE

Event

Q1 2024 Medivir AB Earnings Release
Q1 2024 Medivir AB Earnings Release

Forecast

-

Previous

-
Tuesday, May 7, 2024

Time (UTC)

10:59

Country

SE

Event

Medivir AB Annual Shareholders Meeting
Medivir AB Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 4.408 25.538 13.948 8.724 23.863
Revenue 4.408 25.538 13.948 8.724 23.863
Cost of Revenue, Total 69.078 66.421 46.45 91.063 235.129
Gross Profit -64.67 -40.883 -32.502 -82.339 -211.266
Total Operating Expense 91.762 87.656 56.848 134.703 374.893
Selling/General/Admin. Expenses, Total 20.735 21.415 24.931 35.033 118.177
Research & Development
Depreciation / Amortization 2.571 2.595 4.43 7.085 24.532
Other Operating Expenses, Total 0.632 -0.495 -16.318 1.522 -2.945
Operating Income -87.354 -62.118 -42.9 -125.979 -351.03
Interest Income (Expense), Net Non-Operating -1.411 -0.46 0.28 2.644 0.555
Net Income Before Taxes -88.765 -62.579 -42.62 -123.334 -350.475
Net Income After Taxes -88.765 -63.125 -42.62 -123.44 -350.314
Net Income Before Extra. Items -88.765 -63.125 -42.62 -123.44 -350.314
Total Extraordinary Items
Net Income -88.765 -63.125 -42.62 -123.44 -350.314
Income Available to Common Excl. Extra. Items -88.765 -63.125 -42.62 -123.44 -350.314
Income Available to Common Incl. Extra. Items -88.765 -63.125 -42.62 -123.44 -350.314
Dilution Adjustment
Diluted Net Income -88.765 -63.125 -42.62 -123.44 -350.314
Diluted Weighted Average Shares 55.736 52.815 29.5798 29.5798 29.1755
Diluted EPS Excluding Extraordinary Items -1.5926 -1.19521 -1.44085 -4.17311 -12.0071
Dividends per Share - Common Stock Primary Issue 0 0 0 0 0
Diluted Normalized EPS -1.59323 -1.20358 -1.48676 -4.17311 -12.0062
Unusual Expense (Income) -0.035 -0.68 -1.358 0 0
Total Adjustments to Net Income
Other, Net -0.001 0.001
Interest Expense (Income) - Net Operating -1.219 -1.6 -1.287
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 2 0.4 2.308 1.1 0.5
Revenue 2 0.4 2.308 1.1 0.5
Cost of Revenue, Total 21.2 13.1 15.778 11.1 16.4
Gross Profit -19.2 -12.7 -13.47 -10 -15.9
Total Operating Expense 29 20 20.962 15.7 22.6
Selling/General/Admin. Expenses, Total 7.4 6.2 4.735 3.9 5.8
Depreciation / Amortization 0.7 0.7 0.671 0.7 0.6
Other Operating Expenses, Total -0.3 0 -0.222 0 -0.2
Operating Income -27 -19.6 -18.654 -14.6 -22.1
Interest Income (Expense), Net Non-Operating 0.4 0.7 0.489 -0.2 -1.1
Net Income Before Taxes -26.6 -18.9 -18.065 -14.8 -23.1
Net Income After Taxes -26.6 -18.9 -18.065 -14.8 -23.1
Net Income Before Extra. Items -26.6 -18.9 -18.065 -14.8 -23.1
Net Income -26.6 -18.9 -18.065 -14.8 -23.1
Income Available to Common Excl. Extra. Items -26.6 -18.9 -18.065 -14.8 -23.1
Income Available to Common Incl. Extra. Items -26.6 -18.9 -18.065 -14.8 -23.1
Diluted Net Income -26.6 -18.9 -18.065 -14.8 -23.1
Diluted Weighted Average Shares 55.736 55.736 55.736 55.736 55
Diluted EPS Excluding Extraordinary Items -0.47725 -0.3391 -0.32412 -0.26554 -0.42
Dividends per Share - Common Stock Primary Issue 0 0 0 0 0
Diluted Normalized EPS -0.47725 -0.3391 -0.32412 -0.26554 -0.42
Other, Net 0.1 0.1
Total Adjustments to Net Income
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 123.044 225.917 78.931 152.811 311.64
Cash and Short Term Investments 117.434 221.167 70.007 134.509 286.281
Cash 6.448 14.69 14.038 34.3 47.175
Short Term Investments 110.986 206.477 55.969 100.209 239.106
Total Receivables, Net 2.826 2.74 3.992 11.557 5.538
Accounts Receivable - Trade, Net 0.001 0 0.015 0.063 0.159
Total Inventory
Prepaid Expenses 2.784 2.01 4.932 6.745 19.82
Total Assets 234.197 335.825 191.462 293.462 419.352
Property/Plant/Equipment, Total - Net 14.841 13.597 16.211 23.283 10.828
Property/Plant/Equipment, Total - Gross 33.143 21.356 28.658 38.416 106.498
Accumulated Depreciation, Total -18.302 -7.76 -12.447 -15.133 -95.67
Goodwill, Net
Intangibles, Net 96.312 96.312 96.32 96.341 96.885
Other Long Term Assets, Total -0.001 -0.001
Total Current Liabilities 28.009 41.716 34.67 54.974 96.983
Accounts Payable 3.763 10.338 6.808 12.303 16.335
Accrued Expenses 8.11 29.171 25.414 30.016 50.64
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 14.023 1.153 0.848 5.926 30.008
Total Liabilities 41.408 54.679 49.557 109.006 111.746
Total Long Term Debt 13.399 12.964 14.888 37.153 0
Deferred Income Tax 0
Total Equity 192.789 281.146 141.905 184.456 307.606
Common Stock 27.868 27.868 188.494 188.494 188.494
Additional Paid-In Capital 805.349 804.944 420.804 420.208 420.208
Retained Earnings (Accumulated Deficit) -637.184 -548.419 -463.655 -421.035 -297.595
Other Equity, Total -3.244 -3.247 -3.738 -3.211 -3.501
Total Liabilities & Shareholders’ Equity 234.197 335.825 191.462 293.462 419.352
Total Common Shares Outstanding 55.7242 55.7242 29.5796 29.5796 29.5797
Other Current Assets, Total 0.001
Other Liabilities, Total -0.001 -0.001 16.879 14.763
Note Receivable - Long Term 0 0 21.027
Current Port. of LT Debt/Capital Leases 2.113 1.054 1.6 6.729
Capital Lease Obligations 13.399 12.964 14.888 37.153
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total Current Assets 89.8 105.7 123.044 147.5 168.2
Cash and Short Term Investments 82.8 100.8 117.434 142.2 162.8
Cash 6.3 4.9 6.448 7 4.6
Short Term Investments 76.5 95.9 110.986 135.2 158.2
Total Receivables, Net 7 4.9 2.826 5.3 5.4
Accounts Receivable - Trade, Net 7 4.9 0.001 5.3 5.4
Total Assets 199.8 216.2 234.197 259.3 276.9
Property/Plant/Equipment, Total - Net 13.7 14.1 14.841 15.5 12.4
Intangibles, Net 96.3 96.3 96.312 96.3 96.3
Note Receivable - Long Term
Other Long Term Assets, Total 0.1
Total Current Liabilities 39.4 29.4 28.009 33.9 39.5
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 39.4 29.4 1.46 33.9 39.5
Total Liabilities 51.9 42.3 41.408 48.8 51.6
Total Long Term Debt 12.5 12.8 13.399 14.9 12.1
Capital Lease Obligations 12.5 12.8 13.399 14.9 12.1
Total Equity 147.9 173.9 192.789 210.5 225.3
Common Stock 28.4 27.9 27.868 27.9 27.9
Additional Paid-In Capital 805.6 805.3 805.349 804.9 804.9
Retained Earnings (Accumulated Deficit) -682.9 -656.1 -637.184 -619.1 -604.3
Other Equity, Total -3.2 -3.2 -3.244 -3.2 -3.2
Total Liabilities & Shareholders’ Equity 199.8 216.2 234.197 259.3 276.9
Total Common Shares Outstanding 54.976 55.7246 55.7242 55.7246 55.7246
Prepaid Expenses 2.784
Other Liabilities, Total 0.1
Accounts Payable 3.763
Accrued Expenses 20.673
Current Port. of LT Debt/Capital Leases 2.113
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -88.765 -62.579 -42.62 -123.334 -350.475
Cash From Operating Activities -101.82 -48.734 -58.053 -148.255 -318.63
Cash From Operating Activities 2.571 2.595 4.43 7.086 26.304
Non-Cash Items 0 -16.968 -18.293 30.583
Cash Taxes Paid 0 1.214 -0.799 -1.946 -2.987
Cash Interest Paid 1.315 0.015
Changes in Working Capital -15.626 11.25 -2.895 -13.714 -25.042
Cash From Investing Activities -0.382 0 5.368 4.49 -6.838
Capital Expenditures -0.382 0 -2.684 -1.436 -6.838
Other Investing Cash Flow Items, Total 0 8.052 5.926
Cash From Financing Activities -1.535 199.4 -12.118 -6.659 143.79
Financing Cash Flow Items 0.001 -24.115 -12.713 -6.659 -11.287
Issuance (Retirement) of Stock, Net 0.404 223.515 0.595 0 155.077
Foreign Exchange Effects 0.003 0.494 0.301 -1.349 0.18
Net Change in Cash -103.734 151.16 -64.502 -151.773 -181.498
Issuance (Retirement) of Debt, Net -1.94
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Cash From Operating Activities -16.1 -101.82 -77.1 -57.5 -39.9
Changes in Working Capital -16.1 -101.82 -77.1 -57.5 -39.9
Cash From Investing Activities 0 -0.382 -0.4 0 0
Other Investing Cash Flow Items, Total
Cash From Financing Activities -0.5 -1.535 -1.4 -1 -0.5
Financing Cash Flow Items -0.5 0.001 -1.4 -1 -0.5
Issuance (Retirement) of Stock, Net 0 0.404 0 0
Foreign Exchange Effects 0 0.003 0 0 0
Net Change in Cash -16.6 -103.734 -78.9 -58.5 -40.4
Capital Expenditures 0 -0.382 -0.4 0 0
Issuance (Retirement) of Debt, Net -1.94

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Medivir Company profile

About Medivir AB

Medivir AB is a Sweden-based pharmaceutical research and development company with focus on oncology. The Company specializes in protease inhibitor design and nucleoside and nucleotide science, applying it to development of therapies for cancers with unmet medical need. The Company's clinical pipeline consists of remetinostat, a topical histone deacetylase (HDAC) inhibitor in phase II of clinical studies for the treatment of cutaneous T-cell lymphoma (CTCL), birinapant in combination with Keytruda (pembrolizumab) in phase I of clinical studies for the treatment of solid tumors, MIV-818, a nucleotide-based prodrug in phase I of clinical trials for the treatment of liver cancer, and MIV-711, a cathepsin K (CTSK) inhibitor in IIa extension study for the treatment of osteoarthritis. Furthermore, the Company has additional research projects in cooperation with other institutions.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Medivir AB revenues increased 83% to SEK25.5M. Net loss increased 48% to SEK63.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -SEK1.44 to -SEK1.19.

Equity composition

01/2007, Rigths Issue, 3 new shares for every 5 shares held @ SEK 29 (Factor: 1.224545). 04/2010, Rights Issue, 1 new share for every 4 shares held @ SEK 62 (Factor: 1.10266). 2/2015, complex stock split (Factor: 1.59182) 1/2021, Rights Issue, 1 new share for every 1 share held @ SEK7 (Factor: 1.21788).

Industry: Bio Therapeutic Drugs

Lunastigen 5, 2 tr
HUDDINGE
STOCKHOLM 141 22
SE

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

XRP/USD

0.64 Price
+3.240% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Gold

2,218.08 Price
+1.050% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.30

BTC/USD

70,659.20 Price
+2.540% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

US100

18,236.90 Price
-0.240% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading